# SAB Biotherapeutics share price today (SAB Biotherapeutics, Inc., SABS)

> SAB Biotherapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. SABS · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/sabs

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $3.18 (−0.6% in a year)
- Revenue (Dec 2024): $115 K
- Profit (Dec 2024), incl. one-off: −$11.4 M (one-off item, see below)
- ROE: −131%, FY24

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the SAB Biotherapeutics share price today? SAB Biotherapeutics, Inc.'s share price was $3.18 at the close on 4 November 2026. That is 13.4% below its average price over the last 200 trading days. In the last 52 weeks it traded between $3 and $4, and at that close it sat 35% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 9 weeks running. Over the last 1 year the share price moved +22% while the S&P 500 moved +18%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 4 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does SAB Biotherapeutics pay? SAB Biotherapeutics, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is SAB Biotherapeutics on? SAB Biotherapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is SAB Biotherapeutics profitable? SAB Biotherapeutics, Inc. posted a net loss of $11.4 M in the Dec 2024 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY24 year was a loss of $34.1 M. That loss is 9,908.7% of the quarter's revenue. The same quarter a year earlier lost $5.1 M. 11 of the last 12 reported quarters were loss-making. Read this profit with care: at −$11.4 M it is bigger than the quarter's whole revenue of $115 K. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −8,703.5% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does SAB Biotherapeutics make, and is it growing? SAB Biotherapeutics, Inc. reported $115 K of revenue in the Dec 2024 quarter, −62.3% on the same quarter a year earlier. Over 3 years it has grown −72.1% a year on average. The last full year, FY24, came in at $1.3 M. FY24 revenue was $1.3 M, −41.0% on the year before. Recent pace: the last four quarters grew +30.1% on average, against −72.1% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −60.2%, against −77.7% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does SAB Biotherapeutics keep? SAB Biotherapeutics, Inc.'s sales have fallen to very little: FY24 revenue was $1.3 M, against $60.9 M in FY21. On sales that small an operating margin is not a useful reading, so this section is left out until sales recover. ## Is SAB Biotherapeutics' profit turning into cash? SAB Biotherapeutics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY24 its operations used $34.3 M of cash, against −$34.1 M of profit. After $337 K of spending on assets, free cash was −$34.6 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does SAB Biotherapeutics' cash go? SAB Biotherapeutics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $2.7 M on assets over the last 3 years. Averaged over those years that is 68.1% of FY24 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $2.7 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is SAB Biotherapeutics' P/E ratio, and how does it compare with its own history? SAB Biotherapeutics, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values SAB Biotherapeutics, Inc. at 218.9× its FY24 revenue of $1.3 M. The P/E comes back here once profit turns positive. ## Is the SAB Biotherapeutics business getting better or worse? SAB Biotherapeutics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 10 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does SAB Biotherapeutics earn on its capital? SAB Biotherapeutics, Inc. earned a ROE of −131% in FY24. Its return on capital used (ROIC) is left out: on sales this small it reads −157%, a number that says nothing useful about the business. ## Does SAB Biotherapeutics have too much debt? SAB Biotherapeutics, Inc. has total debt of $5.1 M against shareholder equity of $215 M as of Jun 2026, so its debt is 0.02× its equity, which is very little. Year by year, that ratio went from 0.22 in FY21 to 0.04 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the SAB Biotherapeutics shareholding pattern? 7.7% of SAB Biotherapeutics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 6.3 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is SAB Biotherapeutics from balance-sheet trouble? For SAB Biotherapeutics, Inc., the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does SAB Biotherapeutics rank in its industry? There is no score against its industry: SAB Biotherapeutics, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is SAB Biotherapeutics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to SAB Biotherapeutics in size? SAB Biotherapeutics is the 175th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Century Therapeutics, Inc., vTv Therapeutics Inc. and Ocugen, Inc. Just below it: Fulcrum Therapeutics, Inc., Inhibikase Therapeutics, Inc. and Q32 Bio Inc. ### Biotechnology companies close in size

1. [Century Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/ipsc) $302 million
2. [vTv Therapeutics Inc.](https://www.sectoralpha.in/us/stocks/vtvt) $299 million
3. [Ocugen, Inc.](https://www.sectoralpha.in/us/stocks/ocgn) $297 million
4. SAB Biotherapeutics, Inc. $289 million
5. [Fulcrum Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/fulc) $288 million
6. [Inhibikase Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/ikt) $285 million
7. [Q32 Bio Inc.](https://www.sectoralpha.in/us/stocks/qttb) $267 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Quantum-Si incorporated](https://www.sectoralpha.in/us/stocks/qsi) $285 million · Medical Devices
2. [Kingsway Corporation](https://www.sectoralpha.in/us/stocks/kwy) $284 million · Asset Management
3. SAB Biotherapeutics, Inc. $284 million
4. [EVI Industries, Inc.](https://www.sectoralpha.in/us/stocks/evi) $284 million · Industrial Distribution
5. [Turtle Beach Corporation](https://www.sectoralpha.in/us/stocks/tbch) $283 million · Consumer Electronics

## What else do people ask about SAB Biotherapeutics? ### What were SAB Biotherapeutics's latest quarterly results? SAB Biotherapeutics, Inc. reported revenue of $115 K and a net loss of $11.4 M for the Dec 2024 quarter. Earnings per share were −$1.23. The operating margin was −8,703.5%, 2,515.3 percentage points lower than a year earlier (as of 4 November 2026). ### What is SAB Biotherapeutics's market cap? SAB Biotherapeutics, Inc.'s market capitalisation is $289 M at a stock price of $3.18. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is SAB Biotherapeutics performing? SAB Biotherapeutics, Inc.'s latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 9 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will SAB Biotherapeutics's stock price go up? This page does not forecast SAB Biotherapeutics, Inc.'s stock price. What it shows instead: the stock price is $3.18. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### What could break the SAB Biotherapeutics story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is SAB Biotherapeutics a stock worth studying right now? What the numbers show: SAB Biotherapeutics, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.